Breakdown | |||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|
Income Statement | Total Revenue | ||
108.00K | 498.00K | 0.00 | 32.00K | Gross Profit |
108.00K | 498.00K | 0.00 | 32.00K | EBIT |
-10.05M | -3.08M | -3.33M | -4.65M | EBITDA |
-10.32M | -2.58M | -3.20M | -3.82M | Net Income Common Stockholders |
-10.46M | -2.60M | -3.79M | -4.38M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
1.81M | 2.14M | 58.00K | 653.00K | Total Assets |
4.60M | 2.64M | 135.00K | 953.00K | Total Debt |
694.00K | 0.00 | 0.00 | 1.79M | Net Debt |
-1.12M | -2.14M | -58.00K | 1.14M | Total Liabilities |
4.98M | 2.53M | 2.25M | 3.97M | Stockholders Equity |
-375.00K | 109.00K | -2.11M | -3.01M |
Cash Flow | Free Cash Flow | ||
-6.57M | -2.56M | -2.89M | -3.82M | Operating Cash Flow |
-6.16M | -2.17M | -2.89M | -3.82M | Investing Cash Flow |
-477.00K | -386.00K | 262.00K | 1.60M | Financing Cash Flow |
6.30M | 4.64M | 2.04M | 2.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $30.14M | 8.08 | 18.26% | 14.86% | -5.54% | -27.40% | |
66 Neutral | $50.06M | 8.46 | 40.01% | ― | ― | ― | |
62 Neutral | $11.80B | 10.31 | -7.45% | 2.91% | 7.43% | -7.78% | |
53 Neutral | $35.22M | ― | -16.05% | ― | -9.72% | 25.68% | |
25 Underperform | $43.34M | ― | -748.64% | ― | -51.08% | 11.31% | |
$26.48M | ― | ― | ― | ― | |||
47 Neutral | $48.24M | ― | -198.18% | ― | -24.70% | -371.57% |
On April 30, 2025, Firefly Neurosciences Inc. acquired Evoke Neuroscience, Inc., a medical device company, for $6 million in a deal consisting of cash and stock. This acquisition significantly expands Firefly’s database, intellectual property, and commercial footprint, marking a major step toward building a proprietary foundation model of the human brain. The transaction closed on May 1, 2025, and is expected to enhance Firefly’s industry positioning by leveraging Evoke’s technology and resources, including a large proprietary database and numerous patents. This strategic move aligns with Firefly’s goal of rapid growth and innovation in brain health solutions.
Spark’s Take on AIFF Stock
According to Spark, TipRanks’ AI Analyst, AIFF is a Underperform.
Firefly Neuroscience faces significant financial hurdles, including widening losses and negative equity, which are the most critical factors impacting its stock score. The technical analysis further highlights bearish trends, with the stock trading below key moving averages. The negative P/E ratio and absence of dividends further reflect valuation concerns. Overall, the financial instability and bearish technical indicators result in a low stock score.
To see Spark’s full report on AIFF stock, click here.
Firefly Neuroscience has approved the issuance of shares to BPY Limited and Nomis Bay Ltd. as part of inducement agreements, and entered into settlement agreements with Ian McLean and 1128526 Alberta Ltd. to resolve employment-related disputes. Additionally, David DeCaprio has been appointed as the President and COO, with Arun Menawat filling his previous board committee roles. These developments are part of strategic moves to strengthen company operations and resolve outstanding legal matters.
Spark’s Take on AIFF Stock
According to Spark, TipRanks’ AI Analyst, AIFF is a Underperform.
Firefly Neuroscience faces significant financial hurdles, including widening losses and negative equity, which are the most critical factors impacting its stock score. The technical analysis further highlights bearish trends, with the stock trading below key moving averages. The negative P/E ratio and absence of dividends further reflect valuation concerns. Overall, the financial instability and bearish technical indicators result in a low stock score.
To see Spark’s full report on AIFF stock, click here.
Firefly Neuroscience has appointed Greg Lipschitz as the new Chief Executive Officer, effective March 26, 2025. The company has entered into an Executive Employment Agreement with Lipschitz, which includes a base salary of $300,000 per year, potential bonuses, and stock units. The agreement outlines conditions for severance and equity compensation in case of termination, and includes a confidentiality agreement to protect the company’s proprietary information.
On March 10, 2025, Greg Lipschitz resigned as Executive Chairman of Firefly Neuroscience, Inc., though he remains a director. His resignation was not due to any disagreements with the company’s operations. Arun Menawat was elected as the new Chairman, leading to changes in board committee memberships, including David DeCaprio and Stella Vnook taking new roles. Additionally, Paul Krzywicki, the CFO, received stock options and restricted stock units under the company’s 2024 Long-Term Incentive Plan.